Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
AptarGroup
|
| gptkbp:awards |
industry recognition
|
| gptkbp:businessModel |
strategic partnerships
B2B_and_B2C |
| gptkbp:CEO |
gptkb:Yasmin_A._A._M._A._Alavi
|
| gptkbp:clinicalTrials |
evidence-based practices
collaborations with universities multiple ongoing studies demonstrated in trials published research studies Phase III studies improved patient adherence |
| gptkbp:collaborations |
biotechnology firms
|
| gptkbp:community |
improving quality of life for patients.
|
| gptkbp:communityEngagement |
patient advocacy groups
|
| gptkbp:communitySupport |
local health initiatives
|
| gptkbp:corporateSocialResponsibility |
healthcare_access_initiatives
|
| gptkbp:develops |
medications for ADHD
|
| gptkbp:employees |
approximately 100
|
| gptkbp:financialPerformance |
quarterly reports
|
| gptkbp:financials |
publicly traded company
|
| gptkbp:focusesOn |
central nervous system disorders
|
| gptkbp:founded |
2014
|
| gptkbp:futurePlans |
expand internationally
|
| gptkbp:hasResearchInterest |
consumer insights
|
| gptkbp:headquarters |
gptkb:Dallas,_Texas
|
| gptkbp:healthcare |
high ratings
resources for families |
| https://www.w3.org/2000/01/rdf-schema#label |
Neos Therapeutics
|
| gptkbp:innovation |
focus on patient-centric solutions
|
| gptkbp:investmentFocus |
various venture capital firms
R&D initiatives transparency in communications |
| gptkbp:leadership |
experienced pharmaceutical executives
|
| gptkbp:market |
gptkb:North_America
new formulations competition in the pharmaceutical industry growing in the ADHD space |
| gptkbp:marketSegment |
direct-to-consumer marketing
|
| gptkbp:mission |
improve the lives of patients with ADHD
|
| gptkbp:partnerships |
academic institutions
various healthcare organizations pharmaceutical distributors |
| gptkbp:patentCitation |
multiple drug formulations
|
| gptkbp:products |
adverse event monitoring
Adzenys ER Adzenys XR-ODT Cotempla XR-ODT patient feedback driven unique delivery methods new_therapeutic_approaches |
| gptkbp:regulatoryCompliance |
FDA_approved_products
adheres_to_FDA_regulations |
| gptkbp:research |
grants and investments
|
| gptkbp:research_areas |
psychiatry
|
| gptkbp:researchFocus |
drug delivery systems
|
| gptkbp:researchInterest |
with leading scientists
|
| gptkbp:strategicGoals |
expand product portfolio
|
| gptkbp:supplyChain |
global suppliers
|
| gptkbp:sustainability |
environmental initiatives
|
| gptkbp:technology |
digital health solutions
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:training |
ongoing professional development
|
| gptkbp:website |
www.neostherapeutics.com
|